CVRF's Annual Meetings
----------------------------------------
2020
2019
2018
2017
2016
2015
2014
----------------------------------------
2019
----------------------------------------
2019
TCTAP
FACULTY
PROGRAM
LIVE SITES
ABSTRACTS
CASES
EXHIBITION
FOR ATTENDEE
FACTOID
| Meeting Information
| Course Directors
| Scientific Committee
| Associations and Affiliations
| TCTAP Live Interviews
| Daily Newspaper
| TCTAP Gallery |
| International Faculty
| Korean Faculty
| Course Directors
| E-poster Abstracts
| Guideline for Poster Abstract Presentation
| Program
| Accepted Cases
| Program
| General Information
| Exhibitor's List & Floor Plan
| Registration
| Visa Requirements
| Housing
| Tour Information
| ACT Tour
| Factoid
- Meeting Information
- Course Directors
- Scientific Committee
- Associations and Affiliations
- TCTAP Live Interviews
- Daily Newspaper
- TCTAP Gallery
April 29 (Fri.), 2011
Zilver PTX Stent Showed Beneficial Effect at 24-month Follow up
Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: 24-Month Update
Dr. Mark W. Burket from University of Toledo Medical Center, US presented 24-month
updated data of Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease yesterday. The Zilver® PTX® stent with polymer-free paclitaxel coating is the first drug-eluting stent approved (currently CE marked, investigational in the United States and Japan) for the superficial femoral artery (SFA). This multicenter, multinational, prospective, randomized trial compared the safety and effectiveness of the Zilver PTX study to balloon angioplasty (PTA) and bare metal stenting (BMS). Dr. Burket and colleagues randomized symptomatic patients with SFA lesions (de novo or non-in-stent restenosis) to PTA or Zilver PTX stent placement. PTA patients experiencing acute failure (e.g. >30% residual stenosis) underwent secondary......
Evaluation of LMCA Revascularization by CT Angiography from PRECOMBAT Trial
Conventional coronary angiography (CAG) is recommended 2 to 6 months after left main coronary artery (LM) stenting due to the unpredictable occurrence of in-stent restenosis (ISR), However, CAG for the LM stent has some risks and complications, of which are caused by some complications from the protrusion of the stent to the ascending aorta. Computed tomography coronary angiography (CTCA) is a promising technique for noninvasive coronary evaluation. Dr. Kang and col-leagues valuated the diagnostic performance of high-resolution MSCT to detect ISR after stenting of the LM. 148 patients were prospectively identified in the patient population from the PRE-COMBAT study underwent CTCA before being scheduled for follow-up CAG after LM stenting. Among them, patients with time i n t e r v a l between CTCA and CAG within 1 month were included for analysis (n=48). Twentytwo patients had a Cypher® stent and 26.....